Merck & Company Inc (MRK)vsTravere Therapeutics Inc (TVTX)
MRK
Merck & Company Inc
$144.70
-2.49%
HEALTHCARE · Cap: $368.89B
TVTX
Travere Therapeutics Inc
$49.41
+0.30%
HEALTHCARE · Cap: $4.77B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 11294% more annual revenue ($67.38B vs $591.33M). MRK leads profitability with a 3.6% profit margin vs -7.3%. MRK earns a higher WallStSmart Score of 44/100 (D).
MRK
Hold44
out of 100
Grade: D
TVTX
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-76.6%
Fair Value
$84.66
Current Price
$144.70
$60.04 premium
Margin of Safety
+19.5%
Fair Value
$62.60
Current Price
$49.41
$13.19 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 41.2%
Generating 4.5B in free cash flow
Revenue surging 48.2% year-over-year
Areas to Watch
Trading at 8.5x book value
4.7% revenue growth
ROE of 7.6% — below average capital efficiency
3.6% margin — thin
0.0% earnings growth
Operating margin of 2.3%
Trading at 190.0x book value
ROE of -69.4% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : TVTX
The strongest argument for TVTX centers on Revenue Growth. Revenue growth of 48.2% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Revenue Growth, Return on Equity. A P/E of 151.0x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Bear Case : TVTX
The primary concerns for TVTX are EPS Growth, Operating Margin, Price/Book. Debt-to-equity of 25.16 is elevated, increasing financial risk.
Key Dynamics to Monitor
MRK profiles as a value stock while TVTX is a hypergrowth play — different risk/reward profiles.
TVTX carries more volatility with a beta of 1.14 — expect wider price swings.
TVTX is growing revenue faster at 48.2% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (44/100 vs 31/100). TVTX offers better value entry with a 19.5% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Travere Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development and commercialization of therapies for the treatment of rare diseases. The company is headquartered in San Diego, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?